Clubhouse Meets Masterclass! Wisdom App Launches World’s Largest Mentorship Platform via Social Audio
14.10.2021 19:00:00 EEST | Business Wire | Press release
Wisdom – the social audio app built to democratise mentorship – is now live in the UK, the US, Australia, and Canada. Founded by Dayo Akinrinade, the Wisdom app is an inclusive space where diverse people come together to have conversations that matter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005070/en/
Photo of Dayo Akinrinade, founder and CEO of social audio app Wisdom (Photo: Business Wire)
On a mission to become the next big social audio community, Wisdom taps into the intimacy and authenticity provided by the emerging medium. Drop-in social audio is transforming social networking because it takes interactions and conversations back to their roots. As the oldest medium, and one that is the most “human” of all societal interactions, audio is the antithesis of the heavily filtered nature of today’s visual-led apps and one which helps amplify voices of all groups and communities.
Wisdom is the latest app to launch in the white hot social audio market. Unlike other social audio applications, like Clubhouse, Wisdom is designed from the ground up to promote conversations that matter: conversations of substance on a topic of importance. Members can chat live with experts in dozens of topics from parenting, fitness, and dating to startups, mental health, and beauty. They can listen live or playback the recordings in their own time.
In Wisdom, when a mentor starts a talk, listeners can queue up to ask questions. A timer keeps the conversation moving so no one guest can monopolise the conversation; making sure all voices are heard. Inspired by Tiktok, Wisdom leverages an algorithm-first design that quickly learns what members like to listen to. Talk recommendations are made by a deep-learning neural network.
Dayo Akinrinade, founder and CEO of Wisdom, said: “I founded Wisdom to democratise access to mentorship. During my time at OneTech, London's largest diversity in startups programme, I noticed that diverse individuals from underrepresented groups lack access to mentoring. I also personally experienced how impossible it is to use platforms like LinkedIn for mentoring. The inboxes of experts are inundated with “pick your brain” requests which end up ignored unless the request is via a warm introduction, which is itself a crystallisation of systemic inequality.”
A global platform for mentorship
Connecting with others in a meaningful way has been proven to make people happier, with deep conversations with strangers more enjoyable than small talk. Wisdom will cultivate this, with thousands of people already signed up as mentors, making it the largest platform for mentorship in the world. These experts will be able to use Wisdom to share their knowledge, interact directly with their audience and give back while getting on the ground floor of the next big social audio community.
Though the platform will be free to members, as part of its mission to democratise mentorship, Wisdom will also empower its mentors through monetisation tools so they can grow their own businesses. Monetisation features will be added to Wisdom later this year.
Akinrinade added: “Consider that Masterclass has no more than hundreds of experts on its platform and does not allow deep interactions and is not free. With Wisdom, we are building something very different. Ultimately what we are building with Wisdom is a new social graph … the Mentor Graph. This is not a messy ‘talk graph’ of anyone on any topic but a social graph of the people who can help jumpstart a career, or change a life for the better. People today hunger for conversations that matter. We believe Wisdom is the platform where these conversations can live.”
The Wisdom app is available for download today for iPhone. Android is coming soon.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005070/en/
Contact information
Joyce Omope
joyce@burlington.cc
+44 (0) 7599 672542
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom